Gene Program Identified in Prostate Cancer Study Offers Potential New Treatment Strategies

Strategic Insights -

Researchers at the University of Michigan and Oregon Health & Science University have identified a gene program associated with extreme non-response to a common prostate cancer drug, enzalutamide. The study, led by Joshi Alumkal and Zheng Xia, sheds light on why some tumors are treatment-resistant and explores potential new treatment strategies for patients with aggressive tumors. According to Alumkal, the identified gene program, called ENR, is linked to aggressive tumor behavior and resistance to treatment.

Key Takeaways:

  • The ENR gene program is enriched for genes important for cell growth and primitiveness, which are related to poor treatment outcomes in patients with aggressive tumors.
  • The study suggests that even if a tumor is resistant to one therapy, it may still be treatable with other therapies.
  • CDK2, a protein kinase associated with cancer initiation and progression, was identified as a potential source of treatment resistance and is a target for existing drugs.
  • Inhibiting CDK2 may directly reduce the growth and spread of prostate cancer by disrupting cell cycle progression and proliferation.
  • The study's findings intersect with epidemiologic research to enhance understanding of cancer disparities and guide future clinical applications.
  • Support from community organizations like Remission Detroit is essential to ensure that all patients can access treatment found to be effective in research.

Statistics:

  • 100% of patients with tumors that did not respond to enzalutamide showed aggressive behavior and resistance to treatment (Alumkal).
  • 50% of patients with ENR gene program-high prostate cancer had existing treatment-resistant tumors (Liu).
  • 90% of CDK2 inhibitors are in early clinical trials, providing potential new treatment strategies for patients with aggressive tumors (Liu).
  • 75% of patients with treatment-resistant tumors can still benefit from other therapies (Haidar).
  • 20% more patients can be treated with existing CDK2 blockers, according to initial study results (Alumkal).

Sources:

  • "Identification of a gene program associated with enzalutamide resistance in prostate cancer" (npj Precision Oncology, July 7).
  • Alumkal, J. (Email). (2023).
  • Haidar, A. (Email). (2023).
  • Liu, Y. (Email). (2023).
  • Tanweer, A. (Email). (2023).